These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33897877)

  • 1. Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy.
    Chen X; Xie B; Huang L; Wan J; Wang Y; Shi X; Qiao Y; Song H; Wang H
    Theranostics; 2021; 11(12):5713-5727. PubMed ID: 33897877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dimerization-induced self-assembly of a redox-responsive prodrug into nanoparticles for improved therapeutic index.
    Zhou L; Xie H; Chen X; Wan J; Xu S; Han Y; Chen D; Qiao Y; Zhou L; Zheng S; Wang H
    Acta Biomater; 2020 Sep; 113():464-477. PubMed ID: 32652227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photosensitizer-driven nanoassemblies of homodimeric prodrug for self-enhancing activation and synergistic chemo-photodynamic therapy.
    Zhang S; Wang Z; Kong Z; Wang Y; Zhang X; Sun B; Zhang H; Kan Q; He Z; Luo C; Sun J
    Theranostics; 2021; 11(12):6019-6032. PubMed ID: 33897896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Assembled Nanomedicines for Anticancer and Antibacterial Applications.
    Zhou L; Qiu T; Lv F; Liu L; Ying J; Wang S
    Adv Healthc Mater; 2018 Oct; 7(20):e1800670. PubMed ID: 30080319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate-based amphiphilic prodrug nanoaggregates for co-administration of multiple therapeutics and synergistic cancer therapy.
    Hou M; Gao YE; Shi X; Bai S; Ma X; Li B; Xiao B; Xue P; Kang Y; Xu Z
    Acta Biomater; 2018 Sep; 77():228-239. PubMed ID: 30006314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity.
    Wang H; Lu Z; Wang L; Guo T; Wu J; Wan J; Zhou L; Li H; Li Z; Jiang D; Song P; Xie H; Zhou L; Xu X; Zheng S
    Cancer Res; 2017 Dec; 77(24):6963-6974. PubMed ID: 29055017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-targeted and glutathione-responsive micellar carriers for controlled delivery of cabazitaxel.
    Han X; Gong F; Chi L; Feng C; Sun J; Chen Y; Liu J; Shen Y
    Nanotechnology; 2019 Feb; 30(5):055601. PubMed ID: 30511654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination antitumor therapy with targeted dual-nanomedicines.
    Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
    Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery.
    Li G; Sun B; Li Y; Luo C; He Z; Sun J
    Small; 2021 Dec; 17(52):e2101460. PubMed ID: 34342126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.
    Zhang P; Li J; Ghazwani M; Zhao W; Huang Y; Zhang X; Venkataramanan R; Li S
    Biomaterials; 2015 Oct; 67():104-14. PubMed ID: 26210177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery.
    Wang Z; Chen J; Little N; Lu J
    Acta Biomater; 2020 Jul; 111():20-28. PubMed ID: 32454086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming a highly toxic agent DM1 into injectable safe nanomedicines
    Huang J; Song S; Wang M; Wang H
    Nanoscale; 2023 Jun; 15(23):10110-10124. PubMed ID: 37255385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
    Kwon S; Ko H; You DG; Kataoka K; Park JH
    Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative self-assembly prediction yields targeted nanomedicines.
    Shamay Y; Shah J; Işık M; Mizrachi A; Leibold J; Tschaharganeh DF; Roxbury D; Budhathoki-Uprety J; Nawaly K; Sugarman JL; Baut E; Neiman MR; Dacek M; Ganesh KS; Johnson DC; Sridharan R; Chu EL; Rajasekhar VK; Lowe SW; Chodera JD; Heller DA
    Nat Mater; 2018 Apr; 17(4):361-368. PubMed ID: 29403054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
    Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
    Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
    van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
    Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic efficacy of nanomedicines for prostate cancer: An update.
    Lakshmanan VK
    Investig Clin Urol; 2016 Jan; 57(1):21-9. PubMed ID: 26966723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.
    Wan J; Huang L; Cheng J; Qi H; Jin J; Wang H
    Theranostics; 2021; 11(9):4137-4154. PubMed ID: 33754053
    [No Abstract]   [Full Text] [Related]  

  • 20. Nanomedicine-Cum-Carrier by Co-Assembly of Natural Small Products for Synergistic Enhanced Antitumor with Tissues Protective Actions.
    Wang J; Zhao H; Qiao W; Cheng J; Han Y; Yang X
    ACS Appl Mater Interfaces; 2020 Sep; 12(38):42537-42550. PubMed ID: 32852938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.